[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Personalis Inc (PSNL)

Personalis Inc (PSNL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Personalis Stock Is Up 250% in the Past Year. It Needs to Turn a Profit Next.

Valued at $1.8 billion, Personalis (PSNL) is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient’s cancer and immune response. 

I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals and superior current momentum. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. PSNL checks those boxes. The Trend Seeker issued a new “Buy” signal on Aug. 10. Since then, the stock has gained 17.39%.

Fundamentals

See More
  • Market Capitalization, $K 1,806,437
  • Shares Outstanding, K 104,721
  • Annual Sales, $ 69,650 K
  • Annual Income, $ -81,270 K
  • EBIT $ -114 M
  • EBITDA $ -108 M
  • 60-Month Beta 2.27
  • Price/Sales 25.65
  • Price/Cash Flow N/A
  • Price/Book 7.60

Options Overview Details

View History
  • Implied Volatility 47.45% (+3.52%)
  • Historical Volatility 81.39%
  • IV Percentile 2%
  • IV Rank 1.39%
  • IV High 494.16% on 03/30/26
  • IV Low 41.14% on 07/22/26
  • Expected Move (DTE 23) 1.38 (8.13%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 730
  • Volume Avg (30-Day) 1,721
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 31,763
  • Open Int (30-Day) 19,269
  • Expected Range 15.55 to 18.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.26
  • Number of Estimates 1
  • High Estimate $-0.26
  • Low Estimate $-0.26
  • Prior Year $-0.24
  • Growth Rate Est. (year over year) -8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.52 +47.66%
on 07/29/26
18.89 -9.95%
on 08/21/26
+5.23 (+44.40%)
since 07/24/26
3-Month
8.84 +92.53%
on 05/27/26
18.89 -9.95%
on 08/21/26
+8.07 (+90.27%)
since 05/26/26
52-Week
4.65 +265.62%
on 08/29/25
18.89 -9.95%
on 08/21/26
+12.13 (+248.57%)
since 08/26/25

Most Recent Stories

More News
Personalis Stock Is Up 250% in the Past Year. It Needs to Turn a Profit Next.

Personalis (PSNL) has demonstrated exceptional momentum, gaining nearly 250% over the past year. Shares recently set a new 3-year high. PSNL stock maintains a 100% “Buy” technical opinion from Barchart....

PSNL : 16.97 (-1.62%)
Personalis: Q2 Earnings Snapshot

Personalis: Q2 Earnings Snapshot

PSNL : 16.97 (-1.62%)
Personalis Reports Second Quarter Results and Recent Highlights 

Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2 Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year...

PSNL : 16.97 (-1.62%)
Are BOW, UTZ, PSNL Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

PSNL : 16.97 (-1.62%)
UTZ : 14.23 (-0.14%)
BOW : 33.64 (+0.12%)
Dear Tempus AI Stock Fans, Mark Your Calendars for July 30

Tempus AI is set to report its Q2 results today. Investors will be watching.

PSNL : 16.97 (-1.62%)
TEM : 69.07 (+0.49%)
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--LXP, BLFS, PSNL, and FNWD

NEW YORK , July 29, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

FNWD : 43.54 (+1.11%)
PSNL : 16.97 (-1.62%)
LXP : 61.03 (+0.02%)
BLFS : 37.01 (-0.56%)
Are FNWD, PSNL, DSGR Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

FNWD : 43.54 (+1.11%)
PSNL : 16.97 (-1.62%)
DSGR : 34.81 (+0.03%)
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Personalis ,...

PSNL : 16.97 (-1.62%)
TEM : 69.07 (+0.49%)
Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

PSNL : 16.97 (-1.62%)
ATAI : 7.39 (-0.67%)
LXP : 61.03 (+0.02%)
DSGR : 34.81 (+0.03%)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Personalis, Inc. (NASDAQ: PSNL)

NEW YORK , July 21, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

PSNL : 16.97 (-1.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.

See More

Key Turning Points

3rd Resistance Point 18.23
2nd Resistance Point 17.86
1st Resistance Point 17.55
Last Price 16.97
1st Support Level 16.87
2nd Support Level 16.50
3rd Support Level 16.19

See More

52-Week High 18.89
Last Price 16.97
Fibonacci 61.8% 13.45
Fibonacci 50% 11.77
Fibonacci 38.2% 10.09
52-Week Low 4.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.